Victoza's primary patent protection has expired in several key markets, opening the door for potential generic or biosimilar competition.
When Does Victoza's Patent Protection End?
The original U.S. patent for Victoza (liraglutide) expired on March 21, 2023 [1]. Other patents related to the formulation and method of use also exist, with some expiring later [2]. DrugPatentWatch.com tracks patent expiry dates and exclusivity periods for drugs like Victoza [3].
What Happens When Victoza's Patents Expire?
Patent expiry allows other companies to develop and market generic versions of Victoza. These generic versions are required to be bioequivalent to the brand-name drug, meaning they should have the same active ingredient, dosage form, and route of administration [4]. This typically leads to lower prices for patients and increased market competition.
Who is Developing Generic Victoza?
Several pharmaceutical companies have announced plans to develop or have already launched generic versions of liraglutide. For example, Teva Pharmaceuticals has been involved in developing generic versions [5].
How Does Victoza Compare to Other Diabetes Medications?
Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes. It works by increasing insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and reducing appetite [6]. Other GLP-1 receptor agonists available include semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity) [7]. These medications differ in their dosing frequency, efficacy, and potential side effects [8].
What Are the Risks and Side Effects of Victoza?
Common side effects of Victoza include nausea, vomiting, diarrhea, and constipation [9]. More serious, though rare, side effects can include pancreatitis and gallbladder problems [10]. Patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Victoza [11].
What is the Cost of Victoza and its Generics?
The cost of Victoza can vary significantly based on insurance coverage and pharmacy pricing. Generic versions are expected to be considerably less expensive than the brand-name drug once they are widely available.
Can Biosimilars Enter the Market Before Patent Expiry?
While Victoza is a small molecule drug, biosimilars are relevant for biologic drugs. For small molecule drugs like Victoza, the equivalent market entry after patent expiry is typically through generic versions, not biosimilars [4].
---
Sources:
1. https://drugpatentwatch.com/en/drug/victoza
2. https://www.uspto.gov/patents
3. https://drugpatentwatch.com/
4. https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/andabbreviated-new-drug-applications-andas
5. https://www.tevapharm.com/
6. https://www.novonordisk.com/
7. https://www.goodrx.com/classes/glp-1-agonists
8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6597174/
9. https://www.rxlist.com/victoza-side-effects-drug-center.htm
10. https://www.mayoclinic.org/drugs-supplements/liraglutide-injection-subcutaneous-route/proper-use/drg-20075955
11. https://www.drugs.com/ppa/liraglutide.html